Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.35 USD
Change Today +0.015 / 4.48%
Volume 166.9K
As of 8:10 PM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

labstyle innovations corp (DRIO) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/30/14 - $8.90
52 Week Low
11/14/14 - $0.10
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

labstyle innovations corp (DRIO) Related Bloomberg News

View More Bloomberg News

labstyle innovations corp (DRIO) Related Businessweek News

No Related Businessweek News Found

labstyle innovations corp (DRIO) Details

LabStyle Innovations Corp., a mobile health company, develops and commercializes patent-pending technologies providing consumers with laboratory-testing capabilities using smart phones and other mobile devices. Its products include Dario, a system incorporating patented and proprietary technology that combines a software application and cloud-based data services with self-monitoring of blood glucose device consisting of a lancet, a device-specific disposable test strip cartridge and a smart mobile device-driven glucose reader adaptor. The company is pursuing patent applications in various jurisdictions covering the specific processes related to blood glucose level measurement, as well as various general methods of rapid tests of body fluids using mobile devices and cloud-based services. LabStyle Innovations Corp. was founded in 2011 and is headquartered in Caesarea, Israel.

17 Employees
Last Reported Date: 04/27/15
Founded in 2011

labstyle innovations corp (DRIO) Top Compensated Officers

Acting Chairman, Chief Executive Officer and ...
Total Annual Compensation: $147.6K
Compensation as of Fiscal Year 2014.

labstyle innovations corp (DRIO) Key Developments

LabStyle Innovations Corp. Announces Partnership with Maccabi Healthcare

LabStyle Innovations Corp. (DRIO) announced that in partnership with Maccabi Healthcare, it has launched the comprehensive Dario Diabetes Management Solution as part of Maccabi's advanced Telecare unit (MOMA). The Dario is a proprietary customized diabetes management solution that enables remote treatment for diabetes aiming to improve overall outcomes for patients. Maccabi has integrated the Dario(TM) into MOMA, leveraging LabStyle's cutting edge online and mobile healthcare technologies. Through MOMA, Maccabi is now providing chronic diabetes patients a service of advanced multi-disciplinary support and care through a national call center in coordination with the client's primary physician and other community-based resources. Each MOMA member with diabetes is receiving their own Dario(TM) smart meter for managing and monitoring their diabetes. Caretakers at call centers now have a direct online view and proactive communication over the Dario(TM) mobile platform.

LabStyle Innovations Corp. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

LabStyle Innovations Corp. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported revenues of USD 0.067 million. Operating loss was USD 1.777 million compared to USD 2.668 million a year ago. Net loss was USD 1.638 million compared to USD 2.984 million a year ago. Basic and diluted loss per share was USD 0.08 compared to USD 0.70 a year ago. Net cash used in operating activities was USD 1.525 million compared to USD 2.337 million a year ago. Purchase of property and equipment was USD 0.036 million compared to USD 0.116 million a year ago. Non-GAAP adjusted LBITDA was USD 1.573 million for the first quarter of 2015, compared to approximately USD 1.961 million Non-GAAP adjusted LBITDA for the first quarter of 2014. Basic and diluted Non-GAAP adjusted LBITDA per share was USD 0.07 compared to USD 0.46 a year ago.

LabStyle Innovations Receives Health Canada Approval for Commercialization of the Dario Diabetes Management Solution

LabStyle Innovations Corp. announced that it has been granted Health Canada approval to market and sell Dario™ in Canada through their exclusive distributor in Canada Auto Control Medical Inc. (ACM).


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DRIO:US $0.35 USD +0.015

DRIO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for DRIO.
View Industry Companies

Industry Analysis


Industry Average

Valuation DRIO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 60.1x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 46.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LABSTYLE INNOVATIONS CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at